TTM
$17.34B
YoY change
+119.9%
5Y CAGR
+12.1%
Peak year (2025)
$20.09B
Cumulative operating income
$168.07B
Operating Income history chart for AbbVie (ABBV) from 2009 to 2025
Latest: $20.09B
Operating Income growth chart for AbbVie (ABBV) from 2009 to 2025
Latest: +119.9%
Operating Income history table for AbbVie (ABBV) from 2009 to 2025
| 2025 | $20.09B | +119.9% | +$10.95B | ||
| 2024 | $9.14B | -28.4% | −$3.62B | ||
| 2023 | $12.76B | -29.6% | −$5.36B | ||
| 2022 | $18.12B | +1.1% | +$193.00M | ||
| 2021 | $17.92B | +57.7% | +$6.56B | ||
| 2020 | $11.36B | -12.5% | −$1.62B | ||
| 2019 | $12.98B | +103.4% | +$6.60B | ||
| 2018 | $6.38B | -33.1% | −$3.16B | ||
| 2017 | $9.54B | +2.2% | +$205.00M | ||
| 2016 | $9.34B | +23.9% | +$1.80B | ||
| 2015 | $7.54B | +121.0% | +$4.13B | ||
| 2014 | $3.41B | -39.8% | −$2.25B | ||
| 2013 | $5.66B | -2.6% | −$153.00M | ||
| 2012 | $5.82B | +60.7% | +$2.20B | ||
| 2011 | $3.62B | -23.3% | −$1.10B | ||
| 2010 | $4.72B | -4.4% | −$214.79M | ||
| 2009 | $4.93B | — | — |
- 2025$20.09B+119.9%
- 2024$9.14B-28.4%
- 2023$12.76B-29.6%
- 2022$18.12B+1.1%
- 2021$17.92B+57.7%
- 2020$11.36B-12.5%
- 2019$12.98B+103.4%
- 2018$6.38B-33.1%
- 2017$9.54B+2.2%
- 2016$9.34B+23.9%
- 2015$7.54B+121.0%
- 2014$3.41B-39.8%
- 2013$5.66B-2.6%
- 2012$5.82B+60.7%
- 2011$3.62B-23.3%
- 2010$4.72B-4.4%
- 2009$4.93B—
Operating Income values are taken from AbbVie's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current operating income (TTM) is $17.34B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, AbbVie (ABBV) operating income totalled $20.09B – surged 119.9% year-over-year.
Through 2020–2025 (5 years), AbbVie operating income delivered a +12.1% annualised rate; with mixed annual results across the window.
2025 marks the peak operating income at $20.09B, with the historical low of $3.41B recorded in 2014.
AbbVie Operating Income by Year
AbbVie Operating Income 2025: $20.09B
2025's operating income for AbbVie came in at $20.09B, surged 119.9% from 2024. This figure represents the highest annual value in the available history.
AbbVie Operating Income 2024: $9.14B
AbbVie posted operating income of $9.14B in 2024, declined 28.4% below 2023.
AbbVie Operating Income 2023: $12.76B
In 2023, AbbVie reported operating income of $12.76B, declined 29.6% below 2022.
AbbVie Operating Income 2022: $18.12B
AbbVie operating income in 2022 was $18.12B, edged up 1.1% from 2021.
AbbVie Operating Income 2021: $17.92B
AbbVie operating income in 2021 was $17.92B.
See more financial history for AbbVie (ABBV).
Sector peers by Operating Income
Healthcare peers of AbbVie (ABBV), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B | |
| $8.11B |
- $29.70B
- $25.60B
- $23.49B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation